Join us on March 7 for our Educated Patient Summit on Breast Cancer taking place in Miami, FL! 

To start your customized experience click the start button
Customize ?  
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Kidney Cancer

Bradley McGregor, M.D.
Utilizing the data of the CheckMate 9ER trial, researchers believe that combination therapies in the treatment of patients with renal cell carcinoma are the future of the landscape.
Katie Kosko and Jessica Skarzynski
Here’s a look at what’s inside our 2020 Winter issue.
Jessica Skarzynski
Treatments for Renal Cell Carcinoma are showing effectiveness in the short term, but with the help of new trials, researchers are looking to expand their impact for long term treatment.
Dr. Thomas Powles
The landscape for patients with renal cell carcinoma could potentially change as the use of immune checkpoint inhibition shows promise for these patients.
Kristie L. Kahl
MK-6482 demonstrated an objective response rate of 24% among patients with advanced clear cell renal cell carcinoma, according to study findings presented at the 2020 Genitourinary Cancers Symposium.
Kristie L. Kahl
After five years of follow-up, treatment with Opdivo in those with previously treated advanced or metastatic renal cell carcinoma induced superior survival outcomes.
Kristie L. Kahl
More than 50% of patients with previously untreated advanced or metastatic renal cell carcinoma were alive at 42 months after being treated with Opdivo plus Yervoy.
Conor Killmurray
Children with higher birth weight and body mass index, as well as taller height, are at a greater risk of developing renal cell carcinoma later in life, according to new study findings.
Kristie L. Kahl
Findings from a recent study supported further evaluation of comparing anti–PD-1 to anti–PD-L1 therapy to help determine treatment options for patients with cancer.
Jessica Skarzynski
Personalized treatments have changed the cancer landscape, and continue to change it for patients with renal cell carcinoma.

Sign In

Not a member? Sign up now!
Continue without login